The aim of the present study was to investigate the effects of the novel polyamine analog tetrabutyl propanediamine (TBP) on the growth of K562 chronic myelogenous leukemia (CML) cells and the underlying mechanism of these effects. MTT was used for the analysis of cell proliferation and flow cytometry was performed to analyze cell cycle distribution. DNA fragmentation analysis and Annexin V/pro...

Pinelliapedatisecta agglutinin (PPA) has previously been used in labeling fractions of myeloid leukemia cells in our laboratory. We report here that a bacterial expressed recombinant PPA domain b tagged with soluble coxsackie and adenovirus receptor (sCAR-PPAb) preferentially recognized drug resistant cancer cells K562/ADR and H460/5Fu, as compared to their parental cell lines. Pretreatment of ...

Cimicifugoside is a triterpenoid originating from the rhizomes of Cimicifuga simplex, and acts to inhibit the subcellular transport of nucleosides. Cimicifugoside, when used in combination with methotrexate, showed a cellspecific synergic effect on the promonocytic leukemia cell line U937, but not on the chronic myelogenetic leukemia cell line K562. Thymidine uptake was more severely inhibited ...

The calcium channel blocker verapamil has been shown to reverse multidrug resistance (T. Tsuruo et al.. Cancer Res. 41:1967-1972,1981), but the mechanism of action of this agent has not been fully elucidated. A radioactive photoactive analogue of verapamil, V-|Acncor/-.',5-'H(±)-5-|(3,4-dimethoxyphenetyl)methylamino|-2-(3,4-dimethoxyphenyl)2-isopropyl-/V-/>-azidobenzoylpentylamine, was used to...

Nilotinib, a second-generation tyrosine kinase inhibitor (TKI), has been approved for first-line chronic myeloid leukemia (CML) treatment. The improved clinical response of nilotinib over that of the first generation TKI, imatinib, has been thought to be a result of its high potency of inhibition of BCR-ABL kinase. This study aimed to characterize differences between nilotinib and imatinib in t...

Introduction: Chronic myeloid leukemia (CML) is a malignant clonal disorder of hematopoietic stem cells resulting in the increase of myeloid cells, erythroid cells and platelets in the peripheral blood and hyperplasia in bone marrow. The research evaluated the cytotoxic effects of hydro-alcoholic extracts of Lepidium Sativum (Cress plant) shoots before and after flowering on K562 cell line as a...

introduction: in order to determine the multidrug resistance (mdr) phenotype due to p-glycoprotein expression in haematological malignancies including acute myeloblastic leukemia (aml), a well-characterized p-gp expressing cell line was required to validate and standardize flow cytometric assays and to calibrate instruments. therefore, this resistant subline of k562 was established for the firs...

Herbimycin A, a benzoquinonoid ansamycin antibiotic, is found to reduce intracellular phosphorylation by tyrosine protein kinase. The human chronic myelogenous leukemia cell line K562 expresses a structurally altered c-abl protein with tyrosine kinase activity. When K562 cells are induced to undergo erythroid differentiation by hemin, reduction in the intracellular level of tyrosine phosphoryla...

Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of BCR-ABL-mediated transformation in vitro and in vivo. To investigate whether PTP1B modulates the biological effects of the abl kinase inhibitor STI571 in BCR-ABL-positive cells, we transfected Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia cell-derived K562 cells with either wild-type PTP1B (K562/PTP1B), a subst...